Literature DB >> 20538955

Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport.

Isabelle Sermet-Gaudelus1, Emanuelle Girodon, Dorota Sands, Nathalie Stremmler, Vera Vavrova, Eric Deneuville, Philippe Reix, Stéphanie Bui, Frédéric Huet, Muriel Lebourgeois, Anne Munck, Albert Iron, Veronika Skalicka, Thierry Bienvenu, Delphine Roussel, Gérard Lenoir, Gabriel Bellon, Jacques Sarles, Milan Macek, Michel Roussey, Isabelle Fajac, Aleksander Edelman.   

Abstract

RATIONALE: The diagnosis of cystic fibrosis (CF) is based on a characteristic clinical picture in association with a sweat chloride (Cl(-)) concentration greater than 60 mmol/L or the identification of two CF-causing mutations. A challenging problem is the significant number of children for whom no definitive diagnosis is possible because they present with symptoms suggestive of CF, a sweat chloride level in the intermediate range between 30 and 60 mmol/L, and only one or no identified CF-causing mutation.
OBJECTIVES: To investigate the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in the airways of children with intermediate sweat tests and inconclusive genetic findings in correlation with clinical phenotype and genotype.
METHODS: We developed a composite nasal potential difference (NPD) diagnostic score to discriminate patients with CF from non-CF patients. We tested NPD in 50 children (age, 6 mo to 18 yr) with equivocal diagnoses and correlated the NPD diagnostic score with clinical phenotypes and genotypes.
MEASUREMENTS AND MAIN RESULTS: Fifteen of the 50 children had NPD scores in the CF range. Eight of the 15 carried two CFTR mutations compared with only 5 of the 35 children with normal NPD scores (P = 0.01). They were significantly younger at evaluation and had recurrent lower respiratory tract infections, chronic productive coughs, and chronic Staphylococcus aureus colonization significantly more often than the 35 children with normal NPD results.
CONCLUSIONS: Evaluation of CFTR function in the nasal epithelium of children with inconclusive CF diagnoses can be a useful diagnostic tool and help clinicians to individualize therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538955     DOI: 10.1164/rccm.201003-0382OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  9 in total

1.  Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosis.

Authors:  Courtney M Wheatley; Sarah E Baker; Mary A Morgan; Marina G Martinez; Bo Liu; Steven M Rowe; Wayne J Morgan; Eric C Wong; Stephen R Karpen; Eric M Snyder
Journal:  Respir Med       Date:  2015-05-23       Impact factor: 3.415

2.  Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD).

Authors:  George M Solomon; Inez Bronsveld; Kathryn Hayes; Michael Wilschanski; Paola Melotti; Steven M Rowe; Isabelle Sermet-Gaudelus
Journal:  J Vis Exp       Date:  2018-09-13       Impact factor: 1.355

3.  Refining the continuum of CFTR-associated disorders in the era of newborn screening.

Authors:  H Levy; M Nugent; K Schneck; D Stachiw-Hietpas; A Laxova; O Lakser; M Rock; M K Dahmer; J Biller; S Z Nasr; M Baker; S A McColley; P Simpson; P M Farrell
Journal:  Clin Genet       Date:  2016-01-20       Impact factor: 4.438

4.  Defective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosis.

Authors:  Claudio Sorio; Mario Buffelli; Chiara Angiari; Michele Ettorre; Jan Johansson; Marzia Vezzalini; Laura Viviani; Mario Ricciardi; Genny Verzè; Baroukh Maurice Assael; Paola Melotti
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

5.  The cystic fibrosis lower airways microbial metagenome.

Authors:  Patricia Moran Losada; Philippe Chouvarine; Marie Dorda; Silke Hedtfeld; Samira Mielke; Angela Schulz; Lutz Wiehlmann; Burkhard Tümmler
Journal:  ERJ Open Res       Date:  2016-05-09

6.  Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators.

Authors:  Iwona M Pranke; Aurélie Hatton; Juliette Simonin; Jean Philippe Jais; Françoise Le Pimpec-Barthes; Ania Carsin; Pierre Bonnette; Michael Fayon; Nathalie Stremler-Le Bel; Dominique Grenet; Matthieu Thumerel; Julie Mazenq; Valerie Urbach; Myriam Mesbahi; Emanuelle Girodon-Boulandet; Alexandre Hinzpeter; Aleksander Edelman; Isabelle Sermet-Gaudelus
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

7.  Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?

Authors:  Katharina Niedermayr; Verena Gasser; Claudia Rueckes-Nilges; Dorothea Appelt; Johannes Eder; Teresa Fuchs; Lutz Naehrlich; Helmut Ellemunter
Journal:  Ther Adv Chronic Dis       Date:  2022-08-05       Impact factor: 4.970

8.  Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.

Authors:  Steven M Rowe; Bo Liu; Aubrey Hill; Heather Hathorne; Morty Cohen; John R Beamer; Frank J Accurso; Qunming Dong; Claudia L Ordoñez; Anne J Stone; Eric R Olson; John P Clancy
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

9.  Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study.

Authors:  Azadeh Bagheri-Hanson; Sebastian Nedwed; Claudia Rueckes-Nilges; Lutz Naehrlich
Journal:  BMC Pulm Med       Date:  2014-10-04       Impact factor: 3.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.